| Medical and Health Sciences | Lifetime | 281 | US 152 | 99.99 |
| Biological Sciences | Lifetime | 726 | US 401 | 99.91 |
| Medical and Health Sciences | 2021-2025 | 588 | US 204 | 99.87 |
| Biological Sciences | 2021-2025 | 241 | US 46 | 99.76 |
| Oncology | Lifetime | 34 | US 19 | 99.93 |
| Cancer Research | Lifetime | 30 | US 19 | 99.82 |
| Molecular Biology | Lifetime | 607 | US 374 | 99.70 |
| Pulmonary and Respiratory Medicine | Lifetime | 350 | US 192 | 99.57 |
| Pathology and Forensic Medicine | Lifetime | 145 | US 79 | 99.39 |
| Medical Genetics | Lifetime | 117 | US 68 | 99.15 |
| Hematology | Lifetime | 115 | US 69 | 99.28 |
| Immunology | Lifetime | 624 | US 319 | 98.12 |
| Dermatology | Lifetime | 389 | US 151 | 97.25 |
| Statistics and Probability | Lifetime | 939 | US 510 | 90.42 |
| Hepatology | Lifetime | 740 | US 275 | 86.71 |
| Cancer Research | 2021-2025 | 14 | US 4 | 99.59 |
| Oncology | 2021-2025 | 67 | US 26 | 99.63 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 251 | US 79 | 97.92 |
| Molecular Biology | 2021-2025 | 512 | US 141 | 97.37 |
| Pathology and Forensic Medicine | 2021-2025 | 166 | US 65 | 95.70 |
| Immunology | 2021-2025 | 325 | US 106 | 91.72 |
| Cancer Genomics and Diagnostics | Lifetime | 12 | US 9 | 99.95 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 26 | US 19 | 99.88 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 42 | US 25 | 99.88 |
| Lung Cancer Treatments and Mutations | Lifetime | 51 | US 32 | 99.82 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 25 | US 21 | 99.80 |
| Lymphoma Diagnosis and Treatment | Lifetime | 63 | US 31 | 99.75 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 47 | US 23 | 99.56 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 40 | US 23 | 99.56 |
| Eosinophilic Disorders and Syndromes | Lifetime | 44 | US 26 | 99.44 |
| Colorectal Cancer Treatments and Studies | Lifetime | 95 | US 43 | 99.60 |
| Cancer Treatment and Pharmacology | Lifetime | 117 | US 67 | 99.60 |
| Genetic factors in colorectal cancer | Lifetime | 106 | US 57 | 99.42 |
| Cancer-related Molecular Pathways | Lifetime | 113 | US 73 | 99.46 |
| Cancer Diagnosis and Treatment | Lifetime | 113 | US 64 | 99.13 |
| HER2/EGFR in Cancer Research | Lifetime | 122 | US 63 | 99.44 |
| Viral-associated cancers and disorders | Lifetime | 114 | US 57 | 99.14 |
| CAR-T cell therapy research | Lifetime | 218 | US 139 | 99.25 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 324 | US 158 | 99.08 |
| Acute Myeloid Leukemia Research | Lifetime | 223 | US 114 | 99.36 |
| Tumors and Oncological Cases | Lifetime | 87 | US 56 | 98.85 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 425 | US 202 | 98.79 |
| Autoimmune and Inflammatory Disorders | Lifetime | 59 | US 24 | 98.90 |
| Cancer Mechanisms and Therapy | Lifetime | 111 | US 57 | 98.69 |
| Curcumin's Biomedical Applications | Lifetime | 45 | US 11 | 98.40 |
| Renal cell carcinoma treatment | Lifetime | 237 | US 143 | 98.80 |
| Melanoma and MAPK Pathways | Lifetime | 100 | US 53 | 98.78 |
| Peptidase Inhibition and Analysis | Lifetime | 420 | US 197 | 98.42 |
| Hematological disorders and diagnostics | Lifetime | 110 | US 62 | 98.15 |
| Retinoids in leukemia and cellular processes | Lifetime | 176 | US 101 | 98.12 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 120 | US 57 | 98.51 |
| Neuroendocrine Tumor Research Advances | Lifetime | 439 | US 182 | 98.45 |
| Histiocytic Disorders and Treatments | Lifetime | 58 | US 37 | 98.24 |
| Sarcoma Diagnosis and Treatment | Lifetime | 500 | US 254 | 98.07 |
| Neutropenia and Cancer Infections | Lifetime | 192 | US 99 | 98.07 |
| T-cell and Retrovirus Studies | Lifetime | 210 | US 106 | 97.67 |
| Statistical Methods in Clinical Trials | Lifetime | 166 | US 86 | 97.43 |
| Lung Cancer Research Studies | Lifetime | 535 | US 239 | 98.09 |
| Cancer therapeutics and mechanisms | Lifetime | 466 | US 248 | 97.58 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 663 | US 177 | 98.05 |
| Acute Lymphoblastic Leukemia research | Lifetime | 626 | US 304 | 97.82 |
| Histone Deacetylase Inhibitors Research | Lifetime | 357 | US 188 | 96.69 |
| Protein Degradation and Inhibitors | Lifetime | 411 | US 220 | 96.88 |
| Chromatin Remodeling and Cancer | Lifetime | 122 | US 68 | 96.63 |
| Neuroblastoma Research and Treatments | Lifetime | 628 | US 308 | 96.89 |
| Advanced Breast Cancer Therapies | Lifetime | 346 | US 158 | 97.19 |
| Multiple Myeloma Research and Treatments | Lifetime | 659 | US 295 | 96.80 |
| Cancer Research and Treatments | Lifetime | 923 | US 473 | 95.95 |
| Angiogenesis and VEGF in Cancer | Lifetime | 741 | US 319 | 95.89 |
| Vascular Malformations and Hemangiomas | Lifetime | 281 | US 145 | 95.25 |
| Polyomavirus and related diseases | Lifetime | 559 | US 265 | 95.73 |
| Skin Diseases and Diabetes | Lifetime | 152 | US 69 | 95.63 |
| NF-κB Signaling Pathways | Lifetime | 576 | US 233 | 95.21 |
| Vascular Tumors and Angiosarcomas | Lifetime | 351 | US 184 | 95.72 |
| Blood disorders and treatments | Lifetime | 511 | US 208 | 94.66 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 715 | US 290 | 95.25 |
| Hedgehog Signaling Pathway Studies | Lifetime | 612 | US 297 | 92.90 |
| Economic and Financial Impacts of Cancer | Lifetime | 790 | US 504 | 92.87 |
| Ethics in Clinical Research | Lifetime | 704 | US 375 | 91.59 |
| PARP inhibition in cancer therapy | Lifetime | 887 | US 373 | 91.46 |
| Fibroblast Growth Factor Research | Lifetime | 982 | US 390 | 89.80 |
| Genetic and rare skin diseases. | Lifetime | 600 | US 228 | 88.92 |
| Cancer Genomics and Diagnostics | 2021-2025 | 14 | US 8 | 99.79 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 128 | US 50 | 99.50 |
| Cancer Diagnosis and Treatment | 2021-2025 | 22 | US 7 | 96.74 |
| Chromatin Remodeling and Cancer | 2021-2025 | 9 | US 3 | 96.20 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 158 | US 58 | 98.96 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 177 | US 61 | 98.27 |
| Genetic factors in colorectal cancer | 2021-2025 | 120 | US 57 | 96.84 |
| Cancer Mechanisms and Therapy | 2021-2025 | 60 | US 10 | 95.42 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 220 | US 73 | 97.08 |
| Peptidase Inhibition and Analysis | 2021-2025 | 226 | US 67 | 95.13 |
| Tumors and Oncological Cases | 2021-2025 | 61 | US 25 | 92.85 |
| CAR-T cell therapy research | 2021-2025 | 787 | US 421 | 95.43 |
| Lung Cancer Research Studies | 2021-2025 | 489 | US 158 | 94.44 |
| Galectins and Cancer Biology | 2021-2025 | 104 | US 24 | 89.99 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 495 | US 96 | 92.57 |
| Immunotherapy and Immune Responses | 2021-2025 | 924 | US 307 | 91.20 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 944 | US 379 | 91.13 |
| Melanoma and MAPK Pathways | 2021-2025 | 224 | US 70 | 89.22 |
| Statistical Methods in Clinical Trials | 2021-2025 | 214 | US 87 | 87.93 |
| HER2/EGFR in Cancer Research | 2021-2025 | 717 | US 241 | 88.73 |
| PARP inhibition in cancer therapy | 2021-2025 | 597 | US 229 | 84.68 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 427 | US 151 | 72.86 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 822 | US 291 | 69.21 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 551 | US 193 | 65.27 |
| Fibroblast Growth Factor Research | 2021-2025 | 745 | US 214 | 61.52 |